Anastrozole and Ezetimibe Interaction

Avoid
Mechanism-based 75% confidence

Anastrozole and Ezetimibe have a potentially harmful interaction with 75% confidence. Both Anastrozole and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Half-life: ~40-50 hours Typical dose: 0.25-0.5mg EOD or E3D (estrogen management) pct, anabolic
aromatase androgenicaromatase inhibitorestrogenichepatotoxic
View full profile

Ezetimibe

Cholesterol Absorption Inhibitor | Lipid Management On Cycle

Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle.

Half-life: ~22 hours Typical dose: 10 mg/day cardiovascular
npc1l1 hepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Liver
moderate
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Anastrozole, Ezetimibe). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Anastrozole, Ezetimibe). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Anastrozole, Ezetimibe). Monitor accordingly.

Frequently Asked Questions

Can I take Anastrozole with Ezetimibe?

Combining Anastrozole with Ezetimibe is not recommended. Both Anastrozole and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anastrozole and Ezetimibe safe together?

This combination carries significant risk. Both Anastrozole and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anastrozole and Ezetimibe?

Both Anastrozole and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anastrozole and Ezetimibe?

Anastrozole has a half-life of ~40-50 hours and Ezetimibe has a half-life of ~22 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Anastrozole vs Ezetimibe

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.